Clinical profile and outcomes of hepatocellular carcinoma in primary Budd-Chiari syndrome

Table 2 Baseline characteristics of patients having Budd-Chiari syndrome hepatocellular carcinoma at follow-up and at presentation

Characteristic	BCS-HCC on follow-up, n = 17	BCS-HCC at first presentation, n = 18	P value
Age in yr at onset of BCS	30.0 (24.0-40.0)	32.5 (26.0-38.0)	0.640
Duration of symptoms	3 (2-18)	3 (2-24)	0.880
Sex, males	9 (52.90)	7 (38.88)	0.880
Site of block
Inferior vena cava	4 (23.50)	3 (16.67)	0.450
Hepatic vein	4 (23.50)	6 (33.33)
Combined inferior vena cava and hepatic vein	9 (52.90)	9 (50.00)
Type of block, BCS
Short segment	4 (23.50)	4 (22.22)	0.370
Long segment	13 (76.40)	14 (77.78)
Child class
A	8 (47.1)	13 (72.22)	0.120
B	5 (29.40)	5 (27.78)
C	4 (23.50)	0 (0)
Pain in abdomen	7 (41.18)	7 (38.89)	0.890
Ascites	11 (64.71)	10 (55.56)	0.580
Gastrointestinal bleeding	2 (11.76)	4 (22.22)	0.660
Hepatic encephalopathy at presentation	1 (5.88)	0 (0)	0.490
Hemoglobin in g/dL	10.40 (8.50-11.50)	12.10 (9.75-13.90)	0.110
Total leucocyte count in mm3	4300 (3500-6400)	4735 (4050-6950)	0.610
Platelet count as × 103/mm3	101.0 (71.0-156.0)	150.0 (113.0-166.5)	0.210
Creatinine in mg/dL	0.7 (0.5-0.9)	0.7 (0.6-0.9)	0.550
Total bilirubin in mg/dL	1.8 (1.5-3.2)	1.5 (0.8-2.1)	0.160
Aspartate transaminase in IU/L	66.0 (46.0-120.0)	51.5 (35.0-76.0)	0.280
Alanine transaminase in IU/L	46.0 (27.0-59.0)	42.5 (28.0-66.0)	0.890
Albumin in g/dL	4.0 (2.9-4.7)	4.3 (3.3-4.5)	0.530
Alkaline phosphatase in IU/L	274.0 (178.0-394.0)	210.5 (143.0-300.0)	0.320
Alpha-fetoprotein in ng/mL	500.0 (66.6-1320.0)	13029.0 (500.0-17943.0)	0.010
Intervention received	14 (82.35)	12 (66.67)	0.170
Inferior vena cava angioplasty/stenting	9 (52.90)	6 (33.33)
Hepatic vein angioplasty/stenting	2 (11.70)	2 (11.11)
IVC + HV angioplasty/stenting	0	2 (11.11)
TIPSS	2 (11.70)	2 (11.11)
PSRS	1 (5.80)	0
Barcelona Clinic Liver Cancer staging			0.029
A	1 (5.80)	4 (22.20)
B	10 (58.80)	7 (38.80)
C	2 (11.70)	7 (38.80)
D	4 (23.50)	0

Data are n (%) or median (interquartile range). BCS: Budd-Chiari syndrome; HCC: Hepatocellular carcinoma; HV: Hepatic vein; IVC: Inferior vena cava; PSRS: Proximal splenorenal shunt; TIPSS: Transjugular intrahepatic portosystemic shunt.